[Impact of the Pretreatment or Posttreatment NLR and PLR on the Response of First Line Chemotherapy and the Outcomes in Patients with Advanced Non-small Cell Lung Cancer].

• DOI: 10.3779/j.issn.1009-3419.2018.06.02
• Publication Date: 2018-06-20
• Authors: Fumei Yi; Yangchun Gu; Sen Chen; Yan’e Liu; Wencheng Yin; Yu Zhang; Baoshan Cao
• Keywords: Adult; Aged, 80 and over; Male; Lung Neoplasms; Neutrophils; Response; Neoplasms. Tumors. Oncology. Including cancer and carcinogens; PLR; Middle Aged; Disease-Free Survival; NLR; 03 medical and health sciences; Leukocyte Count; 0302 clinical medicine; Treatment Outcome; Lung neoplasms; Carcinoma, Non-Small-Cell Lung; Humans; Overall survival; Female; Lymphocytes; RC254-282; Aged; Retrospective Studies

Neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte (PLR), indexes of systemic inflammation, have been associated with worse survival for many types cancer. The aim this study is to investigate the impact NLR PLR on overall (OS) explore value changes in treatment as a response indicator non-small cell lung cancer (NSCLC). A total 68 NSCLC patients Peking University Third Hospital were eligible retrospective analysis between April 2008 2015. pretreatment posttreatment all calculated based complete blood counts. Potential prognostic factors such age, gender, performance status, histology, stage, chemotherapy, analyzed. assessed at baseline during chemotherapy treatment. OS was by Kaplan-Meier method. Univariate multivariate Cox regression analyses performed determine associations PLR, clinical features OS. Among cases, values after two cycles (NLR2) (NLR0) (2.69±2.06) (3.94±2.12), respectively. NLR2 significantly lower than NLR0 (P=0.000). There no difference (PLR0) (PLR2) (P<0.05). correlated first line or four chemotherapy. proportion high progression disease 100.0%, higher partial stable disease. NLR0, PLR0 (P<0.05), but not status regimens (P>0.05). According univariate analysis, PLR0, NLR2, 2 4 second third beyond radiotherapy showed that (P=0.004), (P=0.022) (P=0.007) independent indicators patients. well connected outcomes advanced Therefore, may be biomarker predicting potential target management